Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled phase 2 study of QAL964 in rheumatoid arthritis
2013-003493-27Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QAL964 in rheumatoid arthritis (RA) (3 arms), sponsored by Novartis. Primary endpoint: ACR20 response. Started Jan 2014; status: terminated.
02
Drugs
QAL964
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-003493-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003493-27.